| Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216) |
Lutz MP |
Karthaus M |
| Br J Cancer |
Vollpublikation |
2025 |
|
Pankreaskarzinom
|
|
AIO-PAK-0216 |
| doi.org/10.1038/s41416-025-03188-x |
|
|
| Role of pelareorep in activating anti-tumor immunity in PDAC |
Trauger R |
Coffey M |
| J Clin Oncol 43 (no. 16_suppl):2562 |
Abstract |
2025 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2025.43.16_suppl.2562 |
|
|
| 772P - Perioperative atezolizumab with or without the immunomodulatory IMM-101 in patients (pts) with MSI-high (MSI-H) or MMR-deficient (dMMR) stage III colorectal cancer (CRC) ineligible for oxaliplatin-based chemotherapy: The randomised phase II ANTONIO-study (AIO-KRK-0220) |
Karthaus M |
Kasper-Virchow S |
| Ann Oncol 36 (Suppl. 2):532 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
ANTONIO |
AIO-KRK-0220 |
| doi.org/10.1016/j.annonc.2025.08.1345 |
|
|
| 2617P - Coaching of renal cell cancer patients on side effects of systemic cancer treatment: Lessons from the phase III PREPARE trial [PREPARE; AIO-NZK-0115/ass; IAG-N] |
Grünwald V |
Ivanyi P |
| Ann Oncol 36 (Suppl. 2):1405-6 |
Abstract |
2025 |
|
Nierenzellkarzinom
|
PREPARE |
AIO-NZK-0115/ass |
| doi.org/10.1016/j.annonc.2025.08.3232 |
|
|
| 2767P - Patients with extensive stage small-cell lung cancer (ES-SCLC) and poor performance status receiving atezolizumab-carboplatin-etoposide (SPACE): A single-arm phase II AIO study (AIO-TRK-0119) |
Sebastian M |
Reck M |
| Ann Oncol 36 (Suppl. 2):1472-3 |
Abstract |
2025 |
|
Thorakale Onkologie
|
SPACE |
AIO-TRK-0119 |
| doi.org/10.1016/j.annonc.2025.08.3378 |
|
|
| Prospective Head and Neck Carcinoma (r/m SCCHN) Clinical Research Platform for molecular and blood-based biomarkers, treatment and outcome (HEAT) |
Pogorzelski M |
Grünwald V |
| Oncol Res Treat 48 (Suppl 2):17 |
Sonstige |
2025 |
|
Kopf-Hals-Tumoren
|
HEAT |
|
| doi.org/10.1159/000548147 |
|
|
| Effectiveness of Maintenance Therapy with Pembrolizumab vs. Pemetrexed and Pembrolizumab in Advanced Non-Small Cell Lung Cancer: Real-world data from the German Prospective CRISP Registry (AIO-TRK-0315) |
Heinzen S |
Sebastian M |
| Oncol Res Treat 48 (Suppl 2):18 |
Sonstige |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1159/000548147 |
|
|
| Institutional Variability in Testing for Actionable Genetic Alterations in Patients with Stage IIIB/C or IV NSCLC: Real-World Data from the Prospective, Multicenter CRISP Registry (AIO-TRK-0315) |
Althoff FC |
Sebastian M |
| Oncol Res Treat 48 (Suppl 2):199 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1159/000548147 |
|
|
| 2078eP - Combined chemo-immunotherapy versus monoimmunotherapy in advanced high PD-L1-positive NSCLC: Real-world data analyzed with propensity scores technique from the German prospective multicentre registry study (CRISP) |
Metzenmacher M |
|
| Ann Oncol 36 (Suppl. 2):1171 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2699 |
|
|
| 1876P - Effectiveness of maintenance therapy with pembrolizumab vs pemetrexed and pembrolizumab in advanced non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315) |
Heinzen S |
Sebastian M |
| Ann Oncol 36 (Suppl. 2):1079-80 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2500 |
|
|
